Reduction of liver stiffness by antiviral therapy in chronic hepatitis B

Keisuke Osakabe, Naohiro Ichino, Toru Nishikawa, Hiroko Sugiyama, Miho Kato, Shiho Kitahara, Senju Hashimoto, Naoto Kawabe, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Yuko Arima, Koji Suzuki, Kentaro Yoshioka

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy. LS was significantly correlated with fibrosis stage (ρ = 0.686, P < 0.0001). The optimal cut-off values of LS were 7.1 kPa for F ≥ 2, 10.7 kPa for F ≥ 3, and 16.0 kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P < 0.0001). Eleven of 19 (58%) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P = 0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P = 0.0682). LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively.

Original languageEnglish
Pages (from-to)1324-1334
Number of pages11
JournalJournal of Gastroenterology
Volume46
Issue number11
DOIs
Publication statusPublished - 01-11-2011

Fingerprint

Chronic Hepatitis B
Antiviral Agents
Liver
Fibrosis
Therapeutics
Hyaluronic Acid
Liver Cirrhosis
Hepatitis B
Nucleosides
Hepatitis B virus
Nucleotides

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Osakabe, Keisuke ; Ichino, Naohiro ; Nishikawa, Toru ; Sugiyama, Hiroko ; Kato, Miho ; Kitahara, Shiho ; Hashimoto, Senju ; Kawabe, Naoto ; Harata, Masao ; Nitta, Yoshifumi ; Murao, Michihito ; Nakano, Takuji ; Shimazaki, Hiroaki ; Arima, Yuko ; Suzuki, Koji ; Yoshioka, Kentaro. / Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. In: Journal of Gastroenterology. 2011 ; Vol. 46, No. 11. pp. 1324-1334.
@article{1b29098cc83c4f19ad48079af64f2150,
title = "Reduction of liver stiffness by antiviral therapy in chronic hepatitis B",
abstract = "Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy. LS was significantly correlated with fibrosis stage (ρ = 0.686, P < 0.0001). The optimal cut-off values of LS were 7.1 kPa for F ≥ 2, 10.7 kPa for F ≥ 3, and 16.0 kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P < 0.0001). Eleven of 19 (58{\%}) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P = 0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P = 0.0682). LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively.",
author = "Keisuke Osakabe and Naohiro Ichino and Toru Nishikawa and Hiroko Sugiyama and Miho Kato and Shiho Kitahara and Senju Hashimoto and Naoto Kawabe and Masao Harata and Yoshifumi Nitta and Michihito Murao and Takuji Nakano and Hiroaki Shimazaki and Yuko Arima and Koji Suzuki and Kentaro Yoshioka",
year = "2011",
month = "11",
day = "1",
doi = "10.1007/s00535-011-0444-4",
language = "English",
volume = "46",
pages = "1324--1334",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "11",

}

Osakabe, K, Ichino, N, Nishikawa, T, Sugiyama, H, Kato, M, Kitahara, S, Hashimoto, S, Kawabe, N, Harata, M, Nitta, Y, Murao, M, Nakano, T, Shimazaki, H, Arima, Y, Suzuki, K & Yoshioka, K 2011, 'Reduction of liver stiffness by antiviral therapy in chronic hepatitis B', Journal of Gastroenterology, vol. 46, no. 11, pp. 1324-1334. https://doi.org/10.1007/s00535-011-0444-4

Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. / Osakabe, Keisuke; Ichino, Naohiro; Nishikawa, Toru; Sugiyama, Hiroko; Kato, Miho; Kitahara, Shiho; Hashimoto, Senju; Kawabe, Naoto; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Arima, Yuko; Suzuki, Koji; Yoshioka, Kentaro.

In: Journal of Gastroenterology, Vol. 46, No. 11, 01.11.2011, p. 1324-1334.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduction of liver stiffness by antiviral therapy in chronic hepatitis B

AU - Osakabe, Keisuke

AU - Ichino, Naohiro

AU - Nishikawa, Toru

AU - Sugiyama, Hiroko

AU - Kato, Miho

AU - Kitahara, Shiho

AU - Hashimoto, Senju

AU - Kawabe, Naoto

AU - Harata, Masao

AU - Nitta, Yoshifumi

AU - Murao, Michihito

AU - Nakano, Takuji

AU - Shimazaki, Hiroaki

AU - Arima, Yuko

AU - Suzuki, Koji

AU - Yoshioka, Kentaro

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy. LS was significantly correlated with fibrosis stage (ρ = 0.686, P < 0.0001). The optimal cut-off values of LS were 7.1 kPa for F ≥ 2, 10.7 kPa for F ≥ 3, and 16.0 kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P < 0.0001). Eleven of 19 (58%) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P = 0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P = 0.0682). LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively.

AB - Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy. LS was significantly correlated with fibrosis stage (ρ = 0.686, P < 0.0001). The optimal cut-off values of LS were 7.1 kPa for F ≥ 2, 10.7 kPa for F ≥ 3, and 16.0 kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P < 0.0001). Eleven of 19 (58%) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P = 0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P = 0.0682). LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively.

UR - http://www.scopus.com/inward/record.url?scp=84655167547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655167547&partnerID=8YFLogxK

U2 - 10.1007/s00535-011-0444-4

DO - 10.1007/s00535-011-0444-4

M3 - Article

C2 - 21822591

AN - SCOPUS:84655167547

VL - 46

SP - 1324

EP - 1334

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 11

ER -